Koers Oxis International Euronext Paris
Aandelen
US6918295014
Farmaceutische producten
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 10,56 mln. 9,66 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -20 mln. -18,29 mln. | Nettowinst (verlies) 2023 | -7 mln. -6,4 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 16,33 mln. 14,94 mln. | Nettoliquiditeiten 2023 | 13,91 mln. 12,73 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,35
x | K/w-verhouding 2023 |
-1,36
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 89,34% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 13-01-21 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 14-12-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 78 | 01-05-23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 11-11-20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 13-01-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+56,99% | 848 mld. | |
+31,64% | 627 mld. | |
+0,03% | 363 mld. | |
+15,43% | 318 mld. | |
+12,67% | 299 mld. | |
+15,51% | 243 mld. | |
+16,72% | 225 mld. | |
+16,35% | 179 mld. | |
+4,13% | 167 mld. |